

Chronic Lymphocytic Leukemia

**Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina**

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> NCT03059251 ML30187
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

**Hoffmann-La Roche**  
Sponsor

**NCT03059251 ML30187**  
Trial Identifiers

***Eligibility Criteria:***

<b>Gender</b> All	<b>Age</b> ≥18 Years	<b>Healthy Volunteers</b> No
----------------------	-------------------------	---------------------------------